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Abstract
Background: Prevention of preterm birth remains one of the most important challenges in maternity care. We
propose a randomised trial with: a simple Candida testing protocol that can be easily incorporated into usual
antenatal care; a simple, well accepted, treatment intervention; and assessment of outcomes from validated,
routinely-collected, computerised databases.
Methods/Design: Using a prospective, randomised, open-label, blinded-endpoint (PROBE) study design, we aim to
evaluate whether treating women with asymptomatic vaginal candidiasis early in pregnancy is effective in
preventing spontaneous preterm birth. Pregnant women presenting for antenatal care <20 weeks gestation with
singleton pregnancies are eligible for inclusion. The intervention is a 6-day course of clotrimazole vaginal pessaries
(100 mg) and the primary outcome is spontaneous preterm birth <37 weeks gestation.
The study protocol draws on the usual antenatal care schedule, has been pilot-tested and the intervention involves
only a minor modification of current practice. Women who agree to participate will self-collect a vaginal swab and
those who are culture positive for Candida will be randomised (central, telephone) to open-label treatment or
usual care (screening result is not revealed, no treatment, routine antenatal care). Outcomes will be obtained from
population databases.
A sample size of 3,208 women with Candida colonisation (1,604 per arm) is required to detect a 40% reduction in
the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group
to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8). Analyses will be by intention to treat.
Discussion: For our hypothesis, a placebo-controlled trial had major disadvantages: a placebo arm would not
represent current clinical practice; knowledge of vaginal colonisation with Candida may change participants’
behaviour; and a placebo with an alcohol preservative may have an independent affect on vaginal flora. These
disadvantages can be overcome by the PROBE study design.
This trial will provide definitive evidence on whether screening for and treating asymptomatic candidiasis in
pregnancy significantly reduces the rate of spontaneous preterm birth. If it can be demonstrated that treating
asymptomatic candidiasis reduces preterm births this will change current practice and would directly impact the
management of every pregnant woman.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000607077
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Preterm birth - burden of disease
Preterm birth (birth before 37 weeks of gestational age)
is the leading cause of perinatal morbidity and mortality
worldwide [1]. Although improvements in neonatal care
have increased survival for preterm infants, prevention
research and knowledge to date have not managed to
reduce the rate of premature birth [1,2]. The frequency
of preterm birth ranges from 5% to 13% in high income
counties and the incidence is increasing [3,4]. Approxi-
mately half the preterm births are due to spontaneous
preterm birth, for which there are no known effective
prevention measures [3].
Preterm birth is associated with admission to neonatal
intensive care, severe morbidity in the first weeks of life,
prolonged hospital stay after birth, and readmission to
hospital in the first year of life [1]. It is implicated in at
least two-thirds of infant deaths and nearly half of long-
term neurologic disability [1]. Surviving infants, especially
those born before 32 weeks gestation, have substantially
increased risks of chronic health disorders; neurodeve-
lopmental impairments (including cerebral palsy, mental
retardation, visual and auditory deficits); difficulties with
motor skills, speaking, writing, mathematics, behaviour,
and physical education; dysfunction in other cognitive
areas, such as attention, visual processing, academic pro-
gress, and executive function; low educational achieve-
ments and employment; and greater needs for services
such as physician visits, occupational or physical therapy,
nursing or medical procedures [1]. Over the first 10 years
of life hospital inpatient admissions, inpatient days and
costs respectively are 130%, 77%, and 443% higher for
children born very preterm than for children born at
term [5]. Even late preterm birth (34 -37 weeks) is asso-
ciated with increased risks of infant death, cerebral palsy
and social isolation [6]. Clearly, prematurity and its asso-
ciated sequelae have an enormous negative psychosocial
and emotional effect on the family.
Infection and preterm birth
Microbiological studies suggest that intrauterine infec-
tions account for 25-40% of preterm births; but this is
likely to be an under-estimate because intrauterine
infection is difficult to detect with conventional culture
techniques [3]. The mechanisms by which intrauterine
infections lead to preterm labour relate to activation of
the innate immune system [7]. Microorganisms are
recognised by pattern-recognition receptors which in
turn elicit the release of inflammatory chemokines and
cytokines [3,7,8]. Microbial endotoxins and proinflam-
matory cytokines stimulate the production of prosta-
glandins, other inflammatory mediators, and matrix-
degrading enzymes [3,7,8]. Prostaglandins stimulate
uterine contractility and initiate labour, while
degradation of extracellular matrix in the fetal mem-
branes leads to preterm prelabour rupture of the mem-
branes [3,7,8].
Recognition that it is ascending infection that leads to
preterm birth has led to a number of studies that have
evaluated the treatment of vaginal infection in preg-
nancy to reduce preterm birth [9-13]. To date, most of
the intervention trials have found little effect on the rate
of preterm birth. Antibiotics prior to pregnancy do not
reduce preterm birth [9]. A Cochrane systematic review
of the effectiveness of antibiotics for the treatment of
bacterial vaginosis to prevent prematurity concludes that
there is “little evidence that screening and treating all
pregnant women with asymptomatic bacterial vaginosis
will prevent preterm birth and its consequences” [12].
Similarly, antibiotic treatment of vaginal Ureaplasma
urealyticum and Chlamydia trachomatis have not signif-
icantly reduced preterm birth rates [10,13]. Finally, there
is a possibility that the use of metronidazole to treat tri-
chomoniasis in pregnancy is associated with an
increased risk of prematurity [11].
In contrast to these negative results, a recent rando-
mised controlled trial of antenatal screening and treat-
ment for bacterial vaginosis, candidiasis and/or
trichomoniasis in early pregnancy (15-19 weeks gesta-
tion) among over 4 000 asymptomatic pregnant women
reduced the spontaneous preterm birth rate by 46%
[14]. The benefit appeared to be limited to those
women who were treated for asymptomatic candidiasis,
however this interpretation is based on post-hoc sub-
group analysis of this trial. On the other hand, two
observational studies that included Candida in preg-
nancy, conducted in low socioeconomic populations in
the USA in the 1980 s [15,16], found no association
with preterm birth although one found a significantly
increased risk of intra-uterine growth retardation among
women with candidiasis (aOR 1.94, 95%CI 1.2-3.1) [16].
Importantly, in the latter, studies screening was per-
formed later in pregnancy (22-30 weeks gestation)
[15,16] and did not include women with low-level Can-
dida colonisation [15]. Such conflicting results empha-
sise the need to evaluate interventions with
appropriately designed randomised clinical trials.
Candidiasis
Candidiasis commonly called “yeast infection” or
“thrush” is a fungal infection (mycosis) which occurs
when there is overgrowth of any of the Candida species,
of which Candida albicans is the most common [17].
Candida is normally found on skin or mucous mem-
branes including the vagina [17]. However, if the envir-
onment becomes imbalanced, such as when the normal
acidity of the mucous membrane changes or when the
hormonal balance changes, Candida can multiply [17].
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ranging from oral thrush and vaginitis, to systemic and
potentially life-threatening diseases. Candida infections
of the latter category are usually confined to severely
immunocompromised persons.
Vaginal candidiasis, usually (90%) due to Candida
albicans, is often harmless and causes no symptoms
[18,19]. However it can also cause vaginal soreness, itch-
ing and discharge [18,20]. Approximately 75% of all
healthy women of fertile age suffer from at least one
episode of vaginal candidiasis, with associated physical
and psychological morbidity and approximately half will
have a recurrence [18,21]. Vaginal candidiasis (referred
to as ‘candidiasis’ in this protocol) is not traditionally
classified as a sexually transmitted infection, since it
occurs in celibate women, and is considered part of the
normal vaginal flora [22]. This does not mean that sex-
ual transmission does not occur, although the contribu-
tion of sexual transmission to the pathogenesis of
infection is unknown [20]. Importantly treatment of
male partners has not been effective in reducing recur-
rence of vaginal candidiasis [23].
Up to 40% of pregnant women may have vaginal colo-
nisation by Candida species, a two-fold increase from
t h ep r e v a l e n c er a t ei nn o n - p r e g n a n tw o m e n
[14-16,24-26]. This association is believed to be driven
by increased levels of circulating oestrogens and deposi-
tion of glycogen and other substrates in the vagina dur-
ing pregnancy [20,27].
Candidiasis and preterm birth
T h er o l eo fCandida colonisation on the pathway to
preterm birth has not been pursued with the vigour
ascribed to bacterial vaginosis and other vaginal organ-
isms, possibly because it is considered a normal vaginal
commensal organism. However, several factors indicate
an association between vaginal candidiasis and preterm
birth:
￿ the rate of spontaneous preterm birth in women
with untreated, asymptomatic candidiasis is higher
than among women with normal flora - 7.6% versus
2.8% (P = 0.009) in a low-risk obstetric population
[14],
￿ in a high-risk population, there was increased rate
of preterm birth among women with non-albicans
Candida compared with uncolonised women (15.4%
versus 11.3%, P = 0.05)[15]
￿ there is a concordance in risk factors for Candida
colonisation and risk factors for preterm birth
including African-American women, maternal medi-
cal conditions, low socio-economic status, and bac-
terial vaginosis [14,15]
￿ Candida can be isolated from the amniotic fluid of
women with spontaneous preterm birth [28,29]
￿ within the oral endothelium Candida increases
gene expression of metalloproteinases [30]. Similar
effects are seen in vitro in the genital tract as Can-
dida increases metalloproteinase 9 production by
chorioamniotic membranes [31]. Metalloproteinase 9
is a connective tissue remodelling protein which has
an important role in the origin of preterm labour
and preterm premature rupture of the membranes.
Furthermore, there is emerging evidence that eradica-
tion of Candida in pregnancy may reduce the risk of
preterm birth and late miscarriage:
￿ Kiss and colleagues reported that screening and
treatment for infections between 15 and 19 weeks of
gestation in 4429 asymptomatic women reduced the
preterm birth rate by 46% [14]. Those with: candi-
diasis (n = 586, 14.1%) were treated with vaginal clo-
trimazole; trichomonas with vaginal metronidazole;
and bacterial vaginosis with vaginal clindamycin.
The benefit appeared to be in women treated for
candidiasis: spontaneous preterm birth occurred in
only 8 of 289 (2.8%) women treated for candidiasis
compared with 22 of 291 (7.6%) women with
untreated candidiasis in the control group (OR 0.35,
95% CI 0.14-0.84 P = 0.009) [27]. However this is a
post-hoc analysis and the numbers are small.
￿ Three reports based on population-based data
(Hungarian Case-Control Surveillance of Congenital
Abnormalities) in over 38,000 women have also
demonstrated that preterm birth was reduced in
those women who were treated with clotrimazole in
pregnancy [32-34]. These results were obtained after
extensive adjustment for confounding variables,
exclusion of significant recall bias, and despite a 65%
excess of urinary tract infections (which predispose
to preterm birth) in the group treated with clotrima-
zole. A competing explanation is that pregnancy out-
comes were better in health conscious women who
sought treatment with clotrimazole. However, this
would be expected to apply also to the women in
this cohort who were treated with metronidazole,
whose rate of preterm births was unchanged. The
authors speculated that the protective effect of clo-
trimazole for preterm birth may be attributable to
the restoration of the normal colonisation of the
female genital tract and its known antibacterial and/
or antiprotozoal effect. Whilst these studies involved
m a n yw o m e na n ds u p p o r tab e n e f i tf r o mt r e a t i n g
Candida, they are observational rather than rando-
mized trials [27].
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cies among low socioeconomic status Latina women
in New York, the 371 women treated with intravagi-
nal azoles for Candida vaginitis were significantly
less likely to deliver preterm than the 859 women
without vaginitis (relative risk 0.51, P = 0.009)[35]
Treatment of Candida in pregnancy
There are no randomised placebo-controlled trials of
clotrimazole in pregnancy to reduce preterm birth. A
Cochrane Systematic review, including 10 trials (1046
women), of treatment for thrush in pregnancy found:
[36] (i) topical treatment to be effective in eradicating
candidiasis, (ii) topical imidazoles (such as clotrimazole)
to be more effective than nystatin, and that (iii) a treat-
ment regimen of 6 or 7 days is superior to those of
shorter duration. Specifically vaginal clotrimazole for 6
days reduced Candida colonisation in pregnancy to 12%
at 3-6 weeks post treatment compared with 58% of
women receiving placebo (OR 0.14, 95%CI 0.06-0.31)
[37]. Two trials involving 81 pregnant women show
treatment lasting 7 days was more effective (98% eradi-
cation) than treatment for 4 days (49% eradication, OR
0.09, 95% CI 0.03-0.24) [38,39]. However, the endpoint
of these trials has been the successful eradication of
Candida and importantly no pregnancy outcomes were
reported. A randomised controlled trial of clotrimazole
is necessary to provide the best evidence of whether
treatment of asymptomatic Candida colonisation
reduces preterm delivery.
Local application of clotrimazole vaginal pessaries or
cream is generally well tolerated [36]. Occasionally skin
reactions (burning, stinging, or redness) can occur. Clo-
trimazole has been used by a large number of pregnant
women and women of childbearing age without any
proven increase in the frequency of malformations or
other direct or indirect harmful effects on the fetus hav-
ing been observed [40]. A large population-based data-
base study did not demonstrate risks to the fetus
following exposure to clotrimazole in pregnancy [41].
Furthermore, the susceptibility of both Candida albi-
cans and non-albicans Candida vaginal isolates to azole
antifungal agents such as clotrimazole supports the con-
tinued practice of azole antifungal agents for empirical
therapy of uncomplicated Candida vaginitis [42].
Pilot study of clotrimazole to prevent birth in women
with Candida
The methods for the proposed trial have been pilot
tested in an open-label trial of clotrimazole versus usual
care for women with asymptomatic candidiasis [43]. The
pilot study informed the development of the full trial
protocol and achievement of competitive funding. The
results are reported in detail elsewhere, but briefly the
participation rate was 64%; the rate of Candida coloni-
sation in asymptomatic women was 19.8%; women were
not inconvenienced by participation, laboratory testing
and medication dispensing were problem-free; the fol-
low-up rate was 99% and there was a trend to a reduc-
tion in spontaneous preterm birth in the clotrimazole
group. Study procedures, including self-collection of
specimens and treatment administration were well
accepted by participants.
Methods/Design
Aim
to conduct a randomised controlled trial to answer the
clinical question
In women with asymptomatic vaginal candidiasis
early in pregnancy does treatment with clotrimazole
prevent spontaneous preterm birth (less than 37
weeks gestation)?
Hypothesis
that treatment of asymptomatic vaginal candidiasis with
clotrimazole is associated with a 40% reduction in spon-
taneous preterm birth <37 weeks gestation.
Study Design
We will use a prospective, randomised, open-label,
blinded-endpoint (PROBE) study design with 2 arms
[44,45]:
Treatment
6-day treatment with vaginal clotrimazole
Usual care
screening result is not revealed, no treatment, routine
antenatal care
Although, double-blind, placebo-controlled rando-
mised trials are regarded as the ‘gold standard’ of clini-
cal trials, they do have some disadvantages. For our
hypothesis, a placebo arm would not represent current
clinical practice (no screening and no treatment).
Knowledge of vaginal colonisation with Candida may
change participants behaviour such that they seek active
therapy (clotrimazole vaginal preparations are available
over the counter in Australia) rather than, or in addition
to, the study medication [45]. Further, the time, expense
and feasibility of obtaining a placebo preparation should
not be under-estimated [46]. And finally, as a vaginally
administered placebo will necessarily contain an alcohol
preservative, it may be biologically active and the possi-
bility of an independent affect on vaginal flora cannot
be excluded.
These disadvantages can be overcome by a PROBE
study design [44,45]. As in our pilot study, the PROBE
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tion concealment procedures but asymptomatic women
will be randomised to open-label treatment (Canestan
®),
or no treatment and the screening result is not revealed
(consistent with current clinical practice) [43-45]. The
primary endpoint (preterm birth) is unambiguously
defined and those assessing the end-point will be
blinded to the screening results and treatment alloca-
tion. Another advantage of using open-labelled medica-
tion is that patient management adheres more closely to
routine clinical practice than in double-blind, placebo-
controlled trials, making the results more generalisable
to the pragmatic management of patients [44].
Setting
The study will be carried out in at least five participat-
ing maternity hospitals. A range of antenatal care
options are provided in these hospitals including stan-
dard antenatal clinic care, midwifery-led care, birth cen-
tre care, GP-shared care and private obstetric care.
Participants/Eligibility criteria
Pregnant women presenting for antenatal care prior to
20 weeks gestation with singleton pregnancies will be
eligible for inclusion into the study. Treatment by 20
weeks of gestation is likely to be necessary to prevent
preterm birth. Exclusions: women who present beyond
20 weeks gestation or have a history of hypersensitivity
to clotrimazole will be ineligible. Women with sympto-
matic vaginal infection due to Candida will be treated
and are therefore ineligible for the study.
Sample size
A sample size of 3,208 women with Candida colonisa-
tion (1,604 per arm of the trial) is required to detect a
40% reduction in spontaneous preterm births (com-
pared with term birth) among women with asympto-
matic candidiasis from 5.0% in the control group to
3.0% for those women treated with clotrimazole (sig-
nificance 0.05, power 0.8). This is a more conservative
risk reduction than that found in the trial by Kiss
[14], where analysis of this subgroup suggested treat-
ment of asymptomatic candidiasis was associated with
a 65% reduction in spontaneous preterm birth but the
numbers were small and the subgroup analysis was
post-hoc.
Recruitment of 3,208 women will require 16,040
women to be screened based on a Candida carriage rate
of 20%. In our pilot study the Candida carriage rate was
19.6% and the participation rate among eligible women
was 64%. If a participation rate of 64% could be main-
tained across all participating centres, ~25,000 would
need to be approached to achieve screening of 16,040
women. A lower participation rate means more women
would need to be approached. We expect that a partici-
pation rate of at least 60% could be maintained across
all centres and this would mean approaching ~26,000
women.
Recruitment and collection of baseline data
The study procedure is feasible as it draws on usual
antenatal care in pregnancy, and is similar to the Kiss
trial (see Table 1). The research nurse will ask eligible
women to participate, explain the trial and obtain
informed consent, collect baseline data and ask women
to self-collect a vaginal swab. This is only a minor
departure from current practice.
As women of child-bearing age are known to be very
mobile [47], participants will be asked to provide their
parents and other alternative contact details (eg friend
or relative) to enhance subsequent follow-up. Women
will also be asked to specify their preferred method of
contact - women in our pilot study have shown a strong
preference for email contact. Self-collection of vaginal
s w a b si sc o m m o n l yu s e df o rs c r e e n i n gi np r e g n a n c y
[48]. We have also successfully used this method of spe-
cimen collection in a study of vaginal Ureaplasma urea-
lyticum colonisation in pregnancy[49] and in our pilot
study [43]. The detection rate of Candida using self-col-
lection is not different from techniques that are more
invasive, requiring the use of a speculum [50].
Randomisation
Eligible women who are culture positive for Candida
will be randomised to receive active treatment with clo-
trimazole or usual care. The randomisation schedule
will be prepared and centrally administered by a
researcher not involved in patient care. A computer ran-
dom number generator will be used to prepare the ran-
domisation schedule with permuted blocks and 1:1
randomisation. The women randomised to open-label
clotrimazole treatment will be notified by phone by a
research nurse. A central pharmacy will be responsible
for dispensing the study medication which will be sent
to participants by mail from the coordinating centre.
This approach has been acceptable and successful in the
pilot study.
Specimen collection and transport
Surveillance for Candida isolates will be conducted at
12-19 weeks of pregnancy. A vaginal swab will be self-
collected and inoculated immediately into Amies Trans-
port Media, stored at room temperature and transported
to Royal North Shore Hospital (Sydney) within 24 hours.
All swabs will be identified with date of collection,
patient’s study number, packaged according to IATA
guidelines, and transported to Pacific Laboratory Medi-
cine Service (PaLMs), Royal North Shore Hospital.
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vaginal swabs
The detection and identification of Candida from vaginal
swabs is readily achieved. The swab will be inoculated
onto full-plates of chromogenic agar (CHROMagar™-
Candida, CHROMagar, Paris, F r a n c e )t oi s o l a t e ,p r o v i -
sionally speciate and semi-quantitatively enumerate
(scant, moderate, or heavy) Candida species and to
obtain colonies for further work such as susceptibility
testing by broth microdilution methods. This medium is
chosen to ensure detection of mixed infections. Cultures
will be incubated for 72 hours at 35°C in 5% CO2. Identi-
fication to species level will be based on colony morphol-
ogy, and colour.
Intervention
The treatment group will receive a 6-day course of com-
mercially available vaginal clotrimazole pessaries (Cane-
stan
®). Women will be advised to insert one pessary as
gently and deeply as possible into the vagina while lying
on her back, preferably at night, for 6 nights. We have
chosen 6 days of treatment because this is: supported by
the Cochrane Systematic Review of treatment for Can-
dida eradication in pregnancy [36], this is how commer-
cially available vaginal clotrimazole is marketed[40] and
this was the regimen used in the Kiss trial [14]. Women
who miss one or more daily doses will be advised to
insert a single pessary as soon as they remember or the
next evening, and continue using the pessaries until the
course of treatment is finished.
Follow-up
A brief (< 5 minutes) follow-up questionnaire will col-
lect information about symptoms of candidiasis, use of
antibiotics and/or corticosteroids (risk factors for symp-
tomatic candidiasis), treatment of candidiasis (including
study medication, doctor prescribed and over-the-
counter medications), treatment side-effects and compli-
ance with the treatment regimen. The questionnaire will
be web-based with email notification or mailed with a
reply-paid envelope according to the participants stated
preference at trial entry. These secondary outcomes will
be collected at 28-32 weeks, a gestation when the poten-
tial for unmasking the ‘no treatment’ arm will be
irrelevant.
Care of all women and their babies will be otherwise
managed according to the standard practices of the
model of maternity care she has chosen. Women who
develop symptoms of Candida infection will be offered
appropriate treatment. The results of the vaginal swab
culture taken at the time of trial entry will not be dis-
closed nor be available in the pregnancy record.
Outcomes and Explanatory Factors
Baseline data
Brief baseline data will be collected to assess compar-
ability of the study groups. The baseline assessment will
include age, socio-demographic data, smoking and alco-
hol use, medical conditions, history of candidiasis, his-
tory of prior pregnancies including preterm birth,
gestational age at enrolment and method of gestational
age assessment (ultrasound or dates). This information
will be obtained from existing databases (as outlined
below) or where this is not available from the partici-
pants at study entry.
Primary Outcome birth <37 weeks gestation following
spontaneous onset of labour or following preterm prela-
bour rupture of membranes.
The primary and secondary outcomes will be obtained
(with informed consent) from existing computerised
obstetric and hospital databases. This is a novel and
cost-efficient approach [51]. We have previously demon-
strated that the outcomes for this study are reliably col-
lected in routinely collected obstetric and hospital
databases [52-56]. It also allows identification of trans-
fers to another hospital. The latter are uncommon and
we will utilise health record linkage to determine out-
comes for these few women who would otherwise be
lost to follow-up. Consequently, we anticipate negligible
loss to follow-up in this trial. Because this approach is
novel, we will validate the primary outcome (preterm
birth) by reviewing the medical records of all women
Table 1 Trial Schema
Timing (data collection)
Identification & screening of eligible women
(N = 16,040)*
Routine antenatal visit at 12-19 weeks
(baseline data, Candida testing)
↓
Randomisation of women with asymptomatic Candida (n = 3208) < 1 week after Candida testing
Clotrimazole
↓
Usual care
↓
Follow-up Follow-up 28-32 weeks gestation (questionnaire)
↓↓
Birth Birth Primary and secondary outcomes collected from obstetric database
*primary outcome data (preterm birth rates) will be obtained for all women screened regardless of the result.
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preterm, those where gestational age is missing (usually
<1%) and a random sample of those recorded as term
deliveries. We estimate that approximately 300 records
will need to be reviewed to validate preterm birth.
Secondary outcomes Include any preterm birth <37
weeks, medically indicated preterm birth <37 weeks
(including indication), preterm birth <32 weeks, preterm
prelabour rupture of the membranes, spontaneous preg-
nancy loss <20 weeks gestation, fetal growth restriction
(< 10
th birthweight for gestational age percentile), peri-
natal mortality (stillbirth or neonatal death), admission
to neonatal intensive care unit, duration of stay in hos-
pital (maternal and infant), birth weight, Apgar score at
5 minutes, and a composite neonatal morbidity indicator
including respiratory distress, assisted ventilation, intra-
ventricular haemorrhage, necrotising enterocolitis, reti-
nopathy and pneumonia [57].
Other maternal and infant explanatory factors
Other conditions may arise in pregnancy that influence
preterm birth risk including pregnancy hypertension,
gestational diabetes, antepartum haemorrhage, placental
abnormalities (placenta praevia, placental abruption),
congenital anomalies, onset of labour (spontaneous,
induced or no labour) and mode of delivery.
Analyses
Analyses will be by intention to treat. The primary ana-
lysis will compare the proportions of spontaneous pre-
term births in the two groups, using a chi-squared test.
The relative risk and 95% confidence interval of preterm
birth and other outcomes in women with active treat-
ment compared with those with usual care will be calcu-
lated. In the secondary analysis of the primary outcome,
logistic regression will be used to adjust for centre and
any differences in important baseline characteristics.
Secondary outcomes that are binary will be analysed in
a similar manner, while those that are quantitative will
be compared between groups using t-tests or the distri-
bution-free equivalent, as appropriate.
Sub-group analyses will be used to explore associa-
tions between preterm birth and clotrimazole treatment
by degree of Candida colonisation (light, moderate,
heavy), Candida albicans and non-albicans species,
gestational age at enrolment, and among medically indi-
cated preterm births by indication (hypertension, growth
restriction, fetal malformation, placental abnormalities).
To test for differences in the effect of clotrimazole
among sub-groups, a chi-squared test for interaction
will be used, using the trend version for the ordered
variable, degree of colonisation.
Interim analyses: the Data Monitoring Committee
An independent Data Monitoring Committee (DMC)
with established terms of reference and stopping rules
will be appointed to review interim data and other evi-
dence (including updated overviews of relevant rando-
mised controlled trials). The DMC will:
￿ Advise on protocol modifications suggested by
investigators or collaborators (e.g. sample size or
trial endpoint modifications)
￿ Assess the impact and relevance of new external
evidence
￿ Assess data quality, including completeness
￿ Monitor recruitment figures, balance in recruit-
ment by centre and losses to follow-up
￿ Monitor evidence for treatment harm
￿ Monitor planned sample size assumptions
￿ Monitor treatment side-effects and compliance
with the treatment regimen
￿ Recommend that the trial continues to recruit par-
ticipants or that recruitment should be terminated
An interim analysis will be conducted when outcomes
are known for the first 50% of women recruited. The
O’Brien-Fleming method[58] will be used to preserve
the overall P-value at 0.05; for the interim analysis we
will test at P = 0.0031 (z = 2.95430) and for the final
analysis at P = 0.0497 (z = 1.96257) (these calculations
were performed using PASS).
The DMC will inform the Steering Group if in their
view an arm of the study is either clearly indicated or
contra-indicated. The final decision on whether to stop
the trial will rest with the Steering Group.
Ethics Approval
Ethics approval has been granted by the Northern Syd-
ney Central Coast Area Health Human Research Ethics
Committee (Protocol 0907-165M)
Discussion
Prevention of preterm birth remains one of the most
important challenges in modern maternity care. Pro-
viding a Healthy Start to Life, an Australian National
Research Priority, is the goal of this proposal. This
trial will provide definitive evidence on whether
screening and treating of asymptomatic candidiasis in
pregnancy significantly reduces the rate of spontaneous
preterm birth. A significant reduction in preterm birth
would have major resource implications with a com-
mensurate reduction in the need for neonatal facilities,
hospitalisations and longer term care for babies born
preterm.
Roberts et al. BMC Pregnancy and Childbirth 2011, 11:19
http://www.biomedcentral.com/1471-2393/11/19
Page 7 of 9Acknowledgements
This trial is funded by an Australian National Health and Medical Research
Council Project Grant (#632544). Christine Roberts is supported by an
NHMRC Senior Research Fellowship (#457078).
Author details
1Clinical and Population Perinatal Health Research, Kolling Institute of
Medical Research, University of Sydney, NSW Australia.
2Department of
Obstetrics and Gynaecology, University of Sydney, NSW Australia.
3Department of Obstetrics and Gynaecology, Royal North Shore Hospital,
NSW Australia.
4School of Public Health, University of Sydney, NSW Australia.
5Department of Microbiology and Infectious Diseases, Royal North Shore
Hospital, NSW Australia.
6Department of Neonatology, Royal North Shore
Hospital, NSW Australia.
Authors’ contributions
JM conceived the project and all the authors contributed to design of the
study. JM and CR initially drafted the protocol and all authors were involved
in critical revision of the intellectual content. CR, KR and JM obtained ethics
approval for the trial. CR and KR negotiated access to population health data
for outcome assessment. All authors approved the final protocol.
Competing interests
The authors declare that they have no competing interests.
Received: 23 August 2010 Accepted: 11 March 2011
Published: 11 March 2011
References
1. Saigal S, Doyle LW: An overview of mortality and sequelae of preterm
birth from infancy to adulthood. Lancet 2008, 371(9608):261-269.
2. Iams JD, Romero R, Culhane JF, Goldenberg RL: Primary, secondary, and
tertiary interventions to reduce the morbidity and mortality of preterm
birth. Lancet 2008, 371(9607):164-175.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes
of preterm birth. Lancet 2008, 371(9606):75-84.
4. National Perinatal Statistics Unit: Australia’s Mothers and Babies Reports
[http://www.preru.unsw.edu.au/PRERUWeb.nsf/page/Perinatal+Statistics],
(accessed March 2011).
5. Petrou S: The economic consequences of preterm birth during the first
10 years of life. BJOG 2005, 112(Suppl 1):10-15.
6. Ramachandrappa A, Jain L: Health issues of the late preterm infant.
Pediatr Clin North Am 2009, 56(3):565-577, Table of Contents.
7. Goldenberg RL, Hauth JC, Andrews WW: Intrauterine infection and
preterm delivery. N Engl J Med 2000, 342(20):1500-1507.
8. Goldenberg RL, Andrews WW, Hauth JC: Choriodecidual infection and
preterm birth. Nutr Rev 2002, 60(5 Pt 2):S19-25.
9. Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Copper R, Conner M:
Interconceptional antibiotics to prevent spontaneous preterm birth: a
randomized clinical trial. Am J Obstet Gynecol 2006, 194(3):617-623.
10. Brocklehurst P, Rooney G: Interventions for treating genital chlamydia
trachomatis infection in pregnancy. Cochrane Database Syst Rev 2000, , 2:
CD000054.
11. Gulmezoglu AM: Interventions for treating trichomoniasis in pregnancy.
Cochrane Database Syst Rev 2002, , 3: CD000220.
12. McDonald HM, Brocklehurst P, Gordon A: Antibiotics for treating bacterial
vaginosis in pregnancy. Cochrane Database Syst Rev 2007, , 1: CD000262.
13. Raynes-Greenow CH, Roberts CL, Bell JC, Peat B, Gilbert GL: Antibiotics for
ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev 2004,
, 1: CD003767.
14. Kiss H, Petricevic L, Husslein P: Prospective randomised controlled trial of
an infection screening programme to reduce the rate of preterm
delivery. BMJ 2004, 329(7462):371.
15. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA: Epidemiology and
outcomes associated with moderate to heavy Candida colonization
during pregnancy. Vaginal Infections and Prematurity Study Group. Am J
Obstet Gynecol 1998, 178(2):374-380.
16. Polk BF: Association of Chlamydia trachomatis and Mycoplasma hominis
with intrauterine growth retardation and preterm delivery. The John
Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. Am J
Epidemiol 1989, 129(6):1247-1257.
17. Control of communicable diseases manual: an official report of the
American Public Health Association. Washington, D.C.: American Public
Health Association;, 18 2004.
18. Ferrer J: Vaginal candidosis: epidemiological and etiological factors. Int J
Gynaecol Obstet 2000, 71(Suppl 1):S21-27.
19. Holland J, Young ML, Lee O, S CAC: Vulvovaginal carriage of yeasts other
than Candida albicans. Sex Transm Infect 2003, 79(3):249-250.
20. Sobel JD: Vulvovaginal candidosis. Lancet 2007, 369(9577):1961-1971.
21. Sobel JD: Pathogenesis and treatment of recurrent vulvovaginal
candidiasis. Clin Infect Dis 1992, 14(Suppl 1):S148-153.
22. Sobel JD: Vaginitis. N Engl J Med 1997, 337(26):1896-1903.
23. Fong IW: The value of treating the sexual partners of women with
recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992,
68(3):174-176.
24. Gjerdingen D, Fontaine P, Bixby M, Santilli J, Welsh J: The impact of regular
vaginal pH screening on the diagnosis of bacterial vaginosis in
pregnancy. J Fam Pract 2000, 49(1):39-43.
25. McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W,
Thorsgard K, McFee J: Prevention of premature birth by screening and
treatment for common genital tract infections: results of a prospective
controlled evaluation. Am J Obstet Gynecol 1995, 173(1):157-167.
26. Yim SF, Lyon DJ, Chung TK, Haines CJ: A prospective study of the
microbiological environment of the genitourinary tract in Hong Kong
Chinese women during pregnancy. Aust N Z J Obstet Gynaecol 1995,
35(2):178-181.
27. Hay P, Czeizel AE: Asymptomatic trichomonas and candida colonization
and pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007,
21(3):403-409.
28. Chaim W, Mazor M, Wiznitzer A: The prevalence and clinical significance
of intraamniotic infection with Candida species in women with preterm
labor. Arch Gynecol Obstet 1992, 251(1):9-15.
29. Figueroa R, Garry D, Elimian A, Patel K, Sehgal PB, Tejani N: Evaluation of
amniotic fluid cytokines in preterm labor and intact membranes. J
Matern Fetal Neonatal Med 2005, 18(4):241-247.
30. Claveau I, Mostefaoui Y, Rouabhia M: Basement membrane protein and
matrix metalloproteinase deregulation in engineered human oral
mucosa following infection with Candida albicans. Matrix Biol 2004,
23(7):477-486.
31. Zaga-Clavellina V, Lopez GG, Estrada-Gutierrez G, Martinez-Flores A, Maida-
Claros R, Beltran-Montoya J, Vadillo-Ortega F: Incubation of human
chorioamniotic membranes with Candida albicans induces differential
synthesis and secretion of interleukin-1beta, interleukin-6, prostaglandin
E, and 92 kDa type IV collagenase. Mycoses 2006, 49(1):6-13.
32. Banhidy F, Acs N, Puho EH, Czeizel AE: Rate of preterm births in pregnant
women with common lower genital tract infection: a population-based
study based on the clinical practice. J Matern Fetal Neonatal Med 2009,
22(5):410-418.
33. Czeizel AE, Fladung B, Vargha P: Preterm birth reduction after
clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol
2004, 116(2):157-163.
34. Czeizel AE, Rockenbauer M: A lower rate of preterm birth after
clotrimazole therapy during pregnancy. Paediatr Perinat Epidemiol 1999,
13(1):58-64.
35. Morrison EA, Cushman LF: Prevention of preterm delivery. N Engl J Med
2007, 357(19):1979-1980.
36. Young GL, Jewell D: Topical treatment for vaginal candidiasis (thrush) in
pregnancy. Cochrane Database Syst Rev 2001, , 4: CD000225.
37. Ruiz-Velasco V, Rosas-Arceo J: Prophylactic clotrimazole treatment to
prevent mycoses contamination of the newborn. Int J Gynaecol Obstet
1978, 16(1):70-71.
38. Lebherz TB, Ford LC: Candida albicans vaginitis: the problem is diagnosis,
the enigma is treatment. Chemotherapy 1982, 28(Suppl 1):73-79.
39. Pasquale SA, Lawson J, Sargent EC Jr, Newdeck JP: A dose-response study
with Monistat cream. Obstet Gynecol 1979, 53(2):250-253.
40. MIMS Online: Clotrimazole Prescribing Information. .
41. Rosa FW, Baum C, Shaw M: Pregnancy outcomes after first-trimester
vaginitis drug therapy. Obstet Gynecol 1987, 69(5):751-755.
42. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA:
Antifungal susceptibilities of Candida species causing vulvovaginitis
and epidemiology of recurrent cases. J Clin Microbiol 2005,
43(5):2155-2162.
Roberts et al. BMC Pregnancy and Childbirth 2011, 11:19
http://www.biomedcentral.com/1471-2393/11/19
Page 8 of 943. Roberts CL, Rickard KR, Kotsiou G, Morris JM: Treatment of asymptomatic
vaginal candidiasis in pregnancy to prevent preterm birth: an open-label
pilot randomised controlled trial. BMC Pregnancy and Childbirth 2011,
11:18.
44. Hansson L, Hedner T, Dahlof B: Prospective randomized open blinded
end-point (PROBE) study. A novel design for intervention trials.
Prospective Randomized Open Blinded End-Point. Blood Press 1992,
1(2):113-119.
45. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J: Prospective,
randomized, open-label, blinded-endpoint (PROBE) designed trials yield
the same results as double-blind, placebo-controlled trials with respect
to ABPM measurements. J Hypertens 2003, 21(7):1291-1298.
46. Whitham D, Slicocks P, Whitehouse W, Hodgson S, Sammons H: An
example of problems that arise from clinical trials and how to avoid
them. The Pharmaceutical Journal 2009, , 283: 129-130.
47. Raynes-Greenow CH, Nassar N, Roberts CL: Residential mobility in a cohort
of primiparous women during pregnancy and post-partum. Aust N Z J
Public Health 2008, 32(2):131-134.
48. Tabrizi SN, Pirotta MV, Rudland E, Garland SM: Detection of Candida
species by PCR in self-collected vaginal swabs of women after taking
antibiotics. Mycoses 2006, 49(6):523-524.
49. Oftadeh S: Genito-urinary colonisation with ureaplasmas - diagnostic
aspects. Master of Science in Medicine thesis Sydney: University of Sydney;
2006.
50. van de Wijgert J, Altini L, Jones H, de Kock A, Young T, Williamson AL,
Hoosen A, Coetzee N: Two methods of self-sampling compared to
clinician sampling to detect reproductive tract infections in Gugulethu,
South Africa. Sex Transm Dis 2006, 33(8):516-523.
51. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM: Long-
term follow-up of the West of Scotland Coronary Prevention Study. N
Engl J Med 2007, 357(15):1477-1486.
52. Ford JB, Roberts CL, Algert CS, Bowen JR, Bajuk B, Henderson-Smart DJ:
Using hospital discharge data for determining neonatal morbidity and
mortality: a validation study. BMC Health Serv Res 2007, 7:188.
53. Lain SJ, Roberts CL, Hadfield RM, Bell JC, Morris JM: How accurate is the
reporting of obstetric haemorrhage in hospital discharge data? A
validation study. Aust N Z J Obstet Gynaecol 2008, 48(5):481-484.
54. NSW Health: Validation study NSW Midwives Data Collection 1998. NSW
Public Health Bulletin 2000, , Supp 1: 97-99.
55. Roberts CL, Bell JC, Ford JB, Hadfield RM, Algert CS, Morris JM: The
accuracy of reporting of the hypertensive disorders of pregnancy in
population health data. Hypertens Pregnancy 2008, 27(3):285-297.
56. Roberts CL, Bell JC, Ford JB, Morris JM: Monitoring the quality of maternity
care: how well are labour and delivery events reported in population
health data? Paediatr Perinat Epidemiol 2009, 23(2):144-152.
57. Lain S, Algert C, Nassar N, Bowen JR, Roberts CL: Incidence of severe
adverse neonatal outcomes: use of a composite indicator in population
data. Australasian Epidemiologist 2010, 17(2):49-50.
58. O’Brien PC, Fleming TR: A multiple testing procedure for clinical trials.
Biometrics 1979, 35:549-556.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/11/19/prepub
doi:10.1186/1471-2393-11-19
Cite this article as: Roberts et al.: Protocol for a randomised controlled trial
of treatment of asymptomatic candidiasis for the prevention of preterm birth
[ACTRN12610000607077]. BMC Pregnancy and Childbirth 2011 11:19. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Roberts et al. BMC Pregnancy and Childbirth 2011, 11:19
http://www.biomedcentral.com/1471-2393/11/19
Page 9 of 9